First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

Abstract Background Platinum‐based chemotherapy remains a first‐line standard of care for approximately 30% of patients with non‐small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the nab‐paclitaxel/carboplatin (nab‐P/C) combination was shown in the...

Full description

Bibliographic Details
Main Authors: Tobias Dechow, Jorge Riera‐Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke, Dagmar Taeuscher, Manfred Welslau, Karin Potthoff
Format: Article
Language:English
Published: Wiley 2021-11-01
Series:Cancer Medicine
Subjects:
carboplatin
Germany
nab‐paclitaxel
non‐small cell lung carcinoma (NSCLC)
real‐world
Online Access:https://doi.org/10.1002/cam4.4310

Internet

https://doi.org/10.1002/cam4.4310

Similar Items